Literature DB >> 19779322

Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.

Vincent Lo Re1, Giovanni Guaraldi, Mary B Leonard, Anthony R Localio, Jennifer Lin, Gabriella Orlando, Lucia Zirilli, Vincenzo Rochira, Jay R Kostman, Pablo Tebas.   

Abstract

OBJECTIVE: Few studies have examined the impact of viral hepatitis on bone mineral density (BMD), and none have done so among HIV-infected patients. Our objective was to determine whether viral hepatitis was associated with low BMD in HIV.
DESIGN: : A cross-sectional study among 1237 HIV-infected patients (625 with viral hepatitis).
METHODS: Dual-energy X-ray absorptiometry scans of the lumbar spine and femoral neck were obtained. Clinical data, hepatitis B and C status, and markers of bone metabolism were determined at dual-energy X-ray absorptiometry scanning. Multivariable logistic regression examined the association between hepatitis and low BMD (Z-score < or =-2.0 at the lumbar spine, femoral neck, or both).
RESULTS: Mean BMD Z-scores were lower among hepatitis-coinfected women at the lumbar spine {-0.15 versus +0.29; difference = -0.44 [95% confidence Interval (CI) -0.65 to -0.23]; P < 0.001} and femoral neck [-0.64 versus -0.39; difference = -0.25 (95% CI -0.44 to -0.06); P = 0.009] compared with HIV-monoinfected women. No differences in mean BMD Z-scores were observed between coinfected and monoinfected men. After adjustment for age, BMI, duration of HIV, antiretroviral use, physical activity, and smoking, viral hepatitis was associated with low BMD among women (adjusted odds ratio 2.87, 95% CI 1.31-6.29) but not men (adjusted odds ratio 1.19, 95% CI 0.74-1.91). Coinfected women had lower mean parathyroid hormone (60.1 versus 68.1 pg/ml; P = 0.02) but similar mean 25-hydroxyvitamin D (19.1 versus 19.6 ng/ml; P = 0.6) and osteocalcin (3.0 versus 3.2 ng/ml; P = 0.8) concentrations than HIV-monoinfected women.
CONCLUSION: Viral hepatitis was associated with a higher risk of low BMD among HIV-infected women but not men.

Entities:  

Mesh:

Year:  2009        PMID: 19779322      PMCID: PMC2837269          DOI: 10.1097/QAD.0b013e32832ec258

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

Review 1.  Hepatic osteodystrophy.

Authors:  S Rouillard; N E Lane
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

Review 2.  AGA technical review on osteoporosis in hepatic disorders.

Authors:  William D Leslie; Charles N Bernstein; Meryl S Leboff
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

3.  The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Authors:  D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

4.  Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha.

Authors:  Linda Gilbert; Xiaofei He; Paul Farmer; Janet Rubin; Hicham Drissi; Andre J van Wijnen; Jane B Lian; Gary S Stein; Mark S Nanes
Journal:  J Biol Chem       Date:  2001-11-26       Impact factor: 5.157

5.  Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease.

Authors:  M P Duarte; M L Farias; H S Coelho; L M Mendonça; L M Stabnov; M do Carmo d Oliveira; R A Lamy; D S Oliveira
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

6.  Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis.

Authors:  G R Corazza; F Trevisani; M Di Stefano; S De Notariis; G Veneto; L Cecchetti; L Minguzzi; G Gasbarrini; M Bernardi
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

7.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

8.  Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study.

Authors:  Michael E Mussolino; Jennifer H Madans; Richard F Gillum
Journal:  Ann Epidemiol       Date:  2003-11       Impact factor: 3.797

9.  Parathyroid hormone (PTH) secretion, PTH mRNA and calcium-sensing receptor mRNA expression in equine parathyroid cells, and effects of interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha on equine parathyroid cell function.

Authors:  R E Toribio; C W Kohn; C C Capen; T J Rosol
Journal:  J Mol Endocrinol       Date:  2003-12       Impact factor: 5.098

10.  Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.

Authors:  Giordano Madeddu; A Spanu; P Solinas; G M Calia; C Lovigu; F Chessa; M Mannazzu; A Falchi; M S Mura; Giuseppe Madeddu
Journal:  Q J Nucl Med Mol Imaging       Date:  2004-03       Impact factor: 2.346

View more
  19 in total

Review 1.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.

Authors:  Vincent Lo Re; Jessica Volk; Craig W Newcomb; Yu-Xiao Yang; Cristin P Freeman; Sean Hennessy; Jay R Kostman; Pablo Tebas; Mary B Leonard; A Russell Localio
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

Review 3.  Incident fractures in HIV-infected individuals: a systematic review and meta-analysis.

Authors:  Stephanie Shiau; Emily C Broun; Stephen M Arpadi; Michael T Yin
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

4.  Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men.

Authors:  Kristine M Erlandson; Jordan E Lake; Myung Sim; Julian Falutz; Carla M Prado; Ana Rita Domingues da Silva; Todd T Brown; Giovanni Guaraldi
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

5.  Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Authors:  D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

6.  Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients.

Authors:  J L Casado; S Bañon; R Andrés; M J Perez-Elías; A Moreno; S Moreno
Journal:  Osteoporos Int       Date:  2013-09-21       Impact factor: 4.507

Review 7.  Classical and emerging roles of vitamin D in hepatitis C virus infection.

Authors:  Julio A Gutierrez; Neil Parikh; Andrea D Branch
Journal:  Semin Liver Dis       Date:  2011-12-21       Impact factor: 6.115

8.  Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection.

Authors:  Dana D Byrne; Craig W Newcomb; Dena M Carbonari; Melissa S Nezamzadeh; Kimberly B F Leidl; Maximilian Herlim; Yu-Xiao Yang; Sean Hennessy; Jay R Kostman; Mary B Leonard; A Russell Localio; Vincent Lo Re
Journal:  J Hepatol       Date:  2014-04-05       Impact factor: 25.083

Review 9.  Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.

Authors:  Roger Bedimo; Naim M Maalouf; Vincent Lo Re
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

10.  Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Authors:  Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.